# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN
- Date: 2026-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Evangeline Moss, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five-week review: second vaccine doses, baclofen titration, physical therapy, and readiness for the first infusion. **S**

## History of present illness

Ms. Jordan returns five weeks after the consultation. Baclofen 5 mg three times a day made her drowsy for the first week; this has passed, and her mornings are less stiff. Mirabegron has helped: she now gets up once most nights. She had a sore arm for a day after the vaccines and no other reaction. She has had no new symptoms and no infection. The physical therapy evaluation requested at intake has not happened: the clinic's therapist with experience in multiple sclerosis has a waiting list, and she has not yet been offered a date. Her employer has agreed to the accommodations she asked for. She would like the infusions on days without teaching. **S**

| Element | Detail |
|---|---|
| Baclofen | Drowsy the first week, now settled; stiffness better |
| Bladder | Up once most nights on mirabegron |
| Physical therapy | Not yet seen; waiting list |
| Work | Accommodations agreed |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or infection |
| Genitourinary | Negative | Urgency better; no burning |
| Musculoskeletal | Positive | Mild morning stiffness |
| Neurological | Negative | No new numbness, weakness or visual change |

4 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily **S**
- Baclofen 10 mg oral tablet, one tablet three times a day **S**
- Mirabegron 25 mg extended-release oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 83.8 kg; BMI 28 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**
- Recombinant zoster vaccine, dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 120/76, pulse 72; temperature 36.6 °C |
| Neurological | Gait unchanged with a cane; modified Ashworth 1+ in both legs; hip flexor strength 4 out of 5, unchanged with baclofen |
| Skin | No rash; vaccine sites healed |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Active primary progressive multiple sclerosis** (G35.B1). Stable, with no infection; ready for ocrelizumab after today's vaccines. **S**
   - Recombinant zoster dose 2 and hepatitis B dose 2 today.
   - First ocrelizumab half-dose in two weeks and the second two weeks later, on days without teaching, with premedication and at least one hour of observation.
   - Infusion center to confirm no active infection before each dose.
2. **Spastic gait and fall risk** (R26.89). Baclofen tolerated with less stiffness and no added weakness. The physical therapy evaluation is overdue. **S**
   - Increase baclofen to 10 mg three times a day.
   - Clinic to ask the physical therapy service today for the first available date, with a second provider if none is offered within three weeks.
   - Daily stretching and her home exercises meanwhile.
3. **Neurogenic bladder** (N31.9). Better on mirabegron; blood pressure unchanged. **S**
   - Continue mirabegron 25 mg daily.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | New or worsening symptoms (relapse, pseudo-relapse with heat or infection) | Every visit | Completed today | No new symptoms |
| Examination | Disability: EDSS and timed 25-foot walk | Every visit, and at least every 6 months | Up to date | EDSS 6.0 five weeks ago; gait unchanged today |
| Imaging | Brain MRI | At diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadolinium | Up to date | Diagnostic MRI five weeks ago; re-baseline due three to six months after the first dose |
| Medication safety | Vaccines before therapy (PCV20, recombinant zoster x2, Tdap, hepatitis B x2) | Inactivated at least 2 weeks and live at least 4 weeks before the first dose | Completed today | Zoster dose 2 and hepatitis B dose 2 today; series complete; first infusion two weeks from today |
| Medication safety | Infusion reactions and infections | Each infusion, and every visit | Completed today | No infection today; premedication and observation planned |
| Examination | Spasticity (modified Ashworth) and baclofen tolerance | Every visit | Completed today | Modified Ashworth 1+; baclofen increased to 10 mg three times a day |
| Examination | Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron | Every visit | Completed today | Nocturia once; blood pressure 120/76 on mirabegron |
| Referral | Falls, walking aids and physical therapy | Every visit | Deferred | Missed: the physical therapy evaluation requested at intake has not happened because of a waiting list. No harm so far: no falls and her gait is unchanged. Corrective action: the clinic asked the service today for the first available date, with a second provider if none is offered within three weeks; daily stretching and home exercises meanwhile |
| Self-management | Workplace accommodation | At intake and with any change | Completed today | Accommodations agreed by her employer |

## Goal progress

- Diagnosis confirmed and classified, vaccines completed at least two weeks before therapy, and a disease-modifying therapy started within ten weeks. In progress; target 2026-06-29. **S**
- No falls through eight months. In progress; target 2026-10-26. **S**
- 25-hydroxyvitamin D at least 30 ng/mL within four months. In progress; target 2026-06-29. **S**
- Up no more than once a night to pass urine within three months. In progress; target 2026-06-29. **S**
- Keep her full teaching and speaking schedule with the accommodations she chooses. In progress; target 2026-10-26. **S**
- No new or enlarging T2 lesions on the re-baseline MRI. In progress; target 2026-10-26. **S**

## Medication changes

- Stopped: Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated **S**
- Started: Baclofen 10 mg oral tablet, one tablet three times a day **S**

## Guideline basis

- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018), American Academy of Neurology (Neurology)
- 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021), MAGNIMS, CMSC and NAIMS (Lancet Neurology)
- Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019), American Academy of Neurology (Neurology)
- OCREVUS (ocrelizumab) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Genentech label)
- Multiple sclerosis in adults: management (NG220) (2022), National Institute for Health and Care Excellence
- Accommodation and Compliance: Multiple Sclerosis (2026), Job Accommodation Network (U.S. Department of Labor)
- Introduction to the Americans with Disabilities Act (2026), U.S. Department of Justice
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026), Aether Forge

## Follow-up

- Ocrelizumab infusions in two and four weeks at the infusion center. Review six weeks after the second infusion with a blood count, CD19 count, vitamin D and the PHQ-9. **S**
- Next scheduled visit 2026-06-29: four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood. **S**
